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Prostate cancer is the most common type of cancer found in men. An advanced form of 
the cancer – castration-resistant prostate cancer – is responsible for over 28 000 deaths in 
the United States every year with no current curative treatments available. As a result, 
new biomarkers and treatments are desperately needed. Putative biomarkers include, for 
example, certain microRNAs – small non-coding RNAs that are involved in the regula-
tion of gene expression – or tumor suppressor genes that are responsive for cell cycle 
regulation. The objective of the thesis was to investigate the expression of several bi-
omarkers in transgenic mouse prostate tissue. The purpose was to establish protocols for 
the in situ hybridization of miR-32, and immunohistochemical staining methods for Ki-
67, Btg2, and Pten – and to investigate their expression in transgenic mouse prostate tis-
sue.  
 
During this thesis, a successful protocol for the immunohistochemistry of Ki-67, Btg2, 
and Pten with PAXgene fixation was established. A working protocol for the in situ hy-
bridization of miR-32 was also established, but with inconsistent staining. A low level of 
miR-32 expression was detected in the dorsolateral lobe of both wild type (WT) and trans-
genic (TG) prostates. Ki-67 was shown to have a low expression in both WT and TG 
prostates. Btg2 was expressed mainly in the basal cells of both WT and TG prostates, 
including the urethra and ductus deferens. Similarily, Pten expression was observed in 
the basal cells of both WT and TG urethra and, additionally, in the prostate. All bi-
omarkers had close to identical expression in both WT and TG prostates.  
  
In conclusion, the protocol established here for the immunohistochemistry of Ki-67, Btg2, 
and Pten is sufficient for further use with commercial PAXgene fixation. However, the 
immunohistochemistry here should be repeated with fresh tissue sections, in order to en-
sure consistent staining of all sections. Further optimization should be attempted with in 
situ hybridization before moving into samples with confirmed prostatic lesions. In the 
future, the protocol established here for Ki-67, Btg2, and Pten can be used in mouse sam-
ples with confirmed prostatic lesions in order to help evaluate their role in prostate car-
cinogenesis, and in the formation of castration resistance.  
Key words: prostate cancer, biomarker, in situ hybridization, immunohistochemistry 
  
TIIVISTELMÄ 
Tampereen ammattikorkeakoulu 
Laboratorioalan koulutusohjelma 
 
ALANEN, OSKU:  
miR-32:n, Ki-67:n, Btg2:n ja Pten:n ilmentyminen transgeenisen hiiren eturauhaskudok-
sessa 
 
Opinnäytetyö 64 sivua, joista liitteitä 2 sivua 
Marraskuu 2014 
Eturauhassyöpä on miesten yleisin syöpä. Kastraatioresistentti eturauhassyöpä on eturau-
hassyövän edistynyt muoto, johon ei ole löydetty parantavaa hoitokeinoa. Kastraatioresis-
tentti eturauhassyöpä on vastuussa yli 28 000 kuolemasta vuosittain USA:ssa. Tästä joh-
tuen uusia biomarkkereita ja hoitokeinoja etsitään jatkuvasti. Mahdollisia biomarkkereita 
voivat olla esimerkiksi mikroRNA:t, jotka ovat geenien ilmentymistä sääteleviä lyhyitä 
ei-koodaavia RNA:ita. Biomarkkereihin voivat kuulua myös eri tuumorisuppressorigee-
nit, jotka ovat osa solusyklin säätelyä. Opinnäytetyön tavoitteena oli tutkia useiden eri 
biomarkkerien ilmentymistä transgeenisen hiiren eturauhaskudoksessa. Opinnäytetyön 
tarkoituksena oli pystyttää in situ hybridisaatio -menetelmä miR-32:n määritykseen sekä 
menetelmä Ki-67:n, Btg2:n ja Pten:n immunohistokemiallista värjäystä varten ja tutkia 
pystytettyjen menetelmien perusteella näiden biomarkkerien ilmentymistä.  
 
Ki-67:n, Btg2:n ja Pten:n määritystä varten pystytettiin yleispätevä immunohistokemial-
linen värjäysmenetelmä PAXgene-fiksauksella. Lisäksi pystytettiin menetelmä miR-32:n 
määritykseen in situ hybridisaation avulla, mutta saatu värjäystulos oli epätasaista. In situ 
hybridisaation tulosten perusteella miR-32 ilmentymistä oli havaittavissa villityypin 
(WT) ja trasgeenisen (TG) hiiren dorsolateraalisessa eturauhaskudoksessa. Ki-67 ilmen-
tyi pienissä määrin WT- ja TG-hiirten dorsaalissa eturauhaskudoksessa. Btg2 ilmentyi 
lähinnä WT- ja TG-hiirten eturauhasen, virtsaputken ja siemenjohtimen basaalisoluissa. 
Pten ilmentyi WT- ja TG-hiirten virtsaputken basaalisoluissa ja heikosti eturauhaskudok-
sessa. WT- ja TG-hiirten ilmentymisessä ei havaittu suurta eroa minkään biomarkkerin 
yhteydessä.  
 
Opinnäytetyössä pystytetty immunohistokemiallinen värjäysmenetelmä on tarpeeksi luo-
tettava jatkotutkimuksia varten. In situ hybridisaation tulosten parantamiseksi tulisi suo-
rittaa lisää menetelmän optimointia. Lisäksi saadut immunohistokemialliset värjäykset 
tulisi toistaa tuoreemmilla kudosleikkeillä, jotta saataisiin selvitettyä syy mahdollisiin 
värjäyseroihin kudosleikkeiden välillä. Tulevaisuudessa opinnäytetyössä pystytettyjä me-
netelmiä voidaan käyttää hyödyksi eturauhassyöpää sairastavien hiirilinjojen tutkimi-
sessa. Tutkimalla ilmentymistä näissä hiirilinjoissa voidaan arvioida näiden biomarkke-
rien roolia eturauhassyövän synnyssä sekä kastraatioresistentin eturauhassyövän muodos-
tuksessa.     
Asiasanat: eturauhassyöpä, biomarkkeri, in situ hybridisaatio, immunohistokemia  
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ABBREVIATIONS AND TERMS 
 
 
ABT  Avidin-biotin technique 
AR Androgen receptor 
ARR2PB  Probasin promoter with two androgen response elements 
AP Anterior prostate 
BCIP  5-bromo-4-chloro-3-indolyl phosphate 
Btg2 B-cell translocation gene 2 
CRPC Castration resistant prostate cancer 
DAB  3,3´-diaminobenzine tetrahydrochloride 
DEPC  Diethylpyrocarbonate 
DIG  Digoxigenin  
DLP Dorsolateral prostate 
EDC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
FFPE Formalin-fixed paraffin embedded 
H&E  Hematoxylin and Eosin 
HIER Heat-induced epitope retrieval 
HRP  Horseradish peroxidase 
ISH  In situ hybridization 
LP Lateral prostate  
NBT  Nitro blue tetrazolium 
PCa  Prostate cancer 
PFA  Paraformaldehyde 
PFPE PAXgene-fixed paraffin embedded  
PIA  Proliferative inflammatory atropy 
PIN Prostatic intraepithelial neoplasia 
PSA Prostate-specific antigen 
PTEN  Phosphatase and tensin homolog 
RISC RNA-induced silencing complex 
TG  Transgenic 
VP Ventral prostate 
WT  Wild type 
3′UTR  3′ untranslated region 
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1 INTRODUCTION 
 
 
This bachelor’s thesis was carried out in the Molecular Biology of Prostate Cancer Group, 
led by Professor Tapio Visakorpi at the Institute of Biosciences and Medical Technology 
(BioMediTech), University of Tampere. The research group is a part of the Prostate Can-
cer Research Center (PCRC) that investigates, for example, the development of  aggres-
sive prostate cancer and putative treatment options. The bachelor’s thesis was supervised 
by Leena Latonen, Ph.D. The objective of this thesis is to study several putative bi-
omarkers in transgenic mouse prostate tissue. To achive this, protocols for the in situ 
hybridization of miR-32 and for the immunohistohemistry of Ki-67, Btg2, and Pten will 
be established, and the expression of these putative biomarkers will be investigated during 
this thesis. 
  
Prostate cancer – or prostate adenocarcinoma (PCa) – is a cancer of the prostate gland. 
Prostate cancer is the most common type of cancer found in men in the USA, with an 
estimation of around 233 000 new diagnoses and 29 480 deaths in 2014. It is estimated 
that around 1 in 7 men will be diagnosed with prostate cancer during their lifetime. 
(American Cancer Society 2014.) An advanced form of the cancer – castration-resistant 
prostate cancer (CRPC) – is accountable for over 28 000 deaths every year, emphasizing 
the need for finding effective treatment options and biomarkers for the detection of ag-
gressive forms of the cancer (Nguyen et al. 2014).  
 
The Molecular Biology of Prostate Cancer group has previously searched for several an-
drogen-regulated microRNAs that may contribute in the development of prostate cancer 
and castration-resistant prostate cancer (CRPC). For this purpose, A transgenic mouse 
line expressing miR-32 in the prostate epithelium was created by the group. The expres-
sion of miR-32 can be studied with a technique called microRNA in situ hybridization, 
which visualizes the expression of a specific nucleic acid sequence inside a tissue (Niel-
sen 2012, 67). The other putative biomarkers, Ki-67, Btg2, and Pten, are proteins that are 
important for the proper functioning of the cell. Their expression can be researched with 
a technique called immunohistochemistry – a technique for visualizing the specific im-
munologic reaction of an antigen and an antibody in a tissue sample (Miller 2002, 421–
423).   
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2 THEORETICAL BACKGROUND 
 
 
2.1 Prostate cancer 
 
 
2.1.1 Background 
 
Prostate cancer (PCa) is a cancer of the prostate gland. The prostate gland is located be-
tween the rectum and the urinary bladder. Development of the prostate is dependent on 
androgens, such as testosterone, made in the testicles. The gland cells in the prostate are 
responsible for making the prostate fluid, which is added to the semen. A cancer of the 
gland cells of the prostate is called prostate adenocarcinoma. There are other possible 
cancers of the prostate, such as small cell carcinoma, but prostate adenocarcinoma is by 
far the most common. (American Cancer Society 2014.) 
 
Prostate cancer is mainly diagnosed in men aged 65 or older, with the average age of 66 
at the time of diagnosis (American Cancer Society 2014). In Finland, 4604 cases of pros-
tate cancer were diagnosed in 2012 with age adjusted incidence of 81.2/100 000 (Finnish 
Cancer Registry 2014). For prostate cancer, there is an expected rise of + 24% in the 
annual number of cases by 2020 (Finnish Cancer Registry 2009). Figure 1 illustrates the 
mean annual number of cases of prostate cancer from 1961 onwards, with predictions up 
to 2020.  
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FIGURE 1. The mean annual number of new cases of prostate cancer. Predictions up to 
the year 2020 are included. Based on the data by Finnish Cancer Registry (2009) 
  
 
2.1.2 Classification, diagnosis, and treatment 
 
Currently, diagnosis of prostate cancer is dependent on histopathological or cytological 
examination of the prostate gland (Damber & Aus 2008). When a patient has elevated 
PSA, a prostate biopsy is recommended (Kawachi et al. 2010). The biopsy is performed 
under local anesthesia, with transrectal ultrasound to guide the biopsy needle (Damber & 
Aus 2008). The biopsy is graded with a Gleason score, which determines the aggressive-
ness of the cancer. The grading is based on hematoxylin & eosin stained sections of the 
biopsy sample, which are used to give a histologic score between two and ten. (Humphrey 
2004.) In addition, PCa can be classified as a low-risk, intermediate-risk or a high-risk 
disease depending on the official classification (disease progression, PSA and Gleason 
score) (Damber & Aus 2008). 
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Treatment of prostate cancer is dependent on the progression of the disease; whether it’s 
localized, locally advanced, or metastatic, has a rising PSA after surgery/radiation, or is 
hormone-resistant. However, the treatment options are usually limited to active surveil-
lance, radical prostatectomy (surgery), radiotherapy, or hormonal therapy. (Damber & 
Aus 2008.) It is estimated that 80% of men with a Gleason score of eight to ten, who have 
undergone radical prostatectomy, will have a biochemical recurrence of prostate cancer 
at 15 years. These high-risk patients have a prostate cancer survival of 57% at 15 years. 
In comparison, patients with an organ-confined disease can reach survival rates of 90% 
at 15 years. (Pierorazio et al. 2010.) As the goal of radical prostatectomy is to remove all 
the cancerous prostate, PSA recurrence is a common indicator of cancer recurrence 
(Freedland & Moul 2007).  
 
Hormonal therapy is usually the next step after PSA recurrence. Androgen deprivation 
therapy has been used since the 1940s for the treatment of advanced prostate cancer (met-
astatic). Possible treatment options include, for example, surgical castration, chemical 
castration, and estrogens. Blocking the effect of androgens on the prostate with anti-an-
drogens is also possible. (Damber & Aus 2008.) However, following androgen-depriva-
tion therapy, the disease will eventually progress into castration resistance, where the 
treatment is no longer effective (Nguyen et al. 2014). While there are no curative treat-
ments for CRPC, several new treatment options, such as the anti-androgen enzalutamide 
and the androgen synthesis inhibitor abiraterone, are available (Scher et al. 2012; De Bono 
et al. 2011). Also, a novel immunotherapy method, Sipuleucel-T has shown promise in 
the treatment of CRPC (Kantoff et al. 2010).  
 
 
2.1.3 Carcinogenesis 
 
Development of prostate cancer is associated with the formation of prostatic intraepithe-
lial neoplasia (PIN) – an abnormal pattern of prostate cells (Bostwick 1989). PIN can be 
observed within the epithelium as neoplastic changes in the lining of the secretory cells, 
prostatic ducts, and acini. This includes nuclear and nucleolar enlargements, which are 
also observed in prostate cancer. In addition, a basal cell layer is still retained with PIN, 
but is notably absent in prostate cancer. (Montironi et al. 2007.)  
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PIN can be divided into two distinct grading systems: low-grade PIN and high-grade PIN. 
Presence of high-grade PIN indicates a significant risk of prostate adenocarsinoma. High-
grade PIN is diagnosed with histopathological analysis of a prostate biopsy. (Pacelli & 
Bostwick 1997.) It is estimated that high-grade PIN can develop into prostatic adenocar-
cinoma within 10 years (Bostwick et al. 2004). Recently, other morphological changes, 
such as proliferative inflammatory atropy (PIA), are suggested to have a connection in 
prostate cancer development to PIN or carcinoma. PIAs are considered to be genetically 
unstable benign lesions that can develop into PIN or carcinoma. (Woenckhaus & Fenic 
2008.)  
 
The initiation of prostate cancer is linked to several molecular level functions, such as 
inflammation, oxidative/DNA damage, and telomere shortening. Further progression of 
PIN to adenocarcinoma is linked to oncogene-induced cellular senescence and many mo-
lecular mechanisms. (Shen & Abate-Shen 2010.) Cellular senescence is a function of the 
cell, which prevents unlimited proliferation driven by oncogenes, working as a tumor-
suppressor mechanism (Campisi 2001). The common tumor suppressor genes Pten and 
P53 are both linked to cellular senescence and cancer progression (Chen et al. 2005). The 
progression into metastatic prostate cancer is largely correlated with the histological grad-
ing and aggressiveness of the cancer. However, the concrete metastatic pathways still 
remain elusive. Most common sites of prostate cancer metastases are lymph nodes, bones, 
lung, and liver. (Bubendorf et al. 2000.) The key molecular processes and genes behind 
PCa progression are shown in figure 2. 
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FIGURE 2. The molecular processes and key genes involved in prostate cancer progres-
sion from normal epithelium to metastasis 
 
 
2.2 Prostate cancer biomarkers 
 
 
2.2.1 MicroRNAs and cancer 
 
Close to 97% of the human genome consists of non-coding DNA. A number of genes in 
these non-coding areas are responsible for encoding microRNAs. (Lin et al. 2006.) Mi-
croRNAs (miRNAs) are small (20-24 nucleotides) non-coding RNAs that regulate gene 
expression post-transcriptionally (NCBI Reference Sequence Database 2013). Recently, 
it has been found that over 60% of protein-coding genes are putative targets of miRNAs 
in humans (Friedman et al. 2009). 
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Of the transcription machinery, polymerase II is responsible for miRNA transcription. 
First, a pri-miRNA is produced by polymerase II. Pri-miRNAs are a group of hairpin-like 
structures that can be either protein-coding or non-coding. One hairpin structure is chosen 
by the Drosha ribonuclease III enzyme, which cleaves a 70-nucleotides-long stem-loop 
precursor miRNA (pre-miRNA) out of the structure. Pre-miRNA is further cleaved by 
Dicer ribonuclease to generate the miRNA and antisense miRNA star (miRNA*) struc-
tures. The miRNA is then linked to a RNA-induced silencing complex (RISC), which can 
attach to the target mRNA with imperfect base pairing. The binding site to the target 
mRNA is generally in the 3′ untranslated region (3′UTR). The attachment of a RISC-
complex to the mRNA leads either into translational inhibition, or into destabilization of 
the mRNA, causing a change in gene expression. (NCBI Reference Sequence Database 
2013.) A simplified version of miRNA biogenesis is shown in figure 3.  
 
 
FIGURE 3. A simplified illustration of the miRNA biosynthesis pathway 
 
Recent evidence suggests that some microRNAs have a role in cancer as oncogenes or 
tumor suppressors. It has been shown that miRNA dysregulation exists in all studied tu-
mor-types, including the prostate. The effect can be similar to dysregulation of oncogenes 
and tumor suppressor genes. This further highlights the importance of identifying all the 
targets of miRNAs in cancer, in order to establish their role in cancer carcinogenesis. It 
has been shown that the dysregulation can be caused by mechanisms such as deletion, 
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amplification, mutation, epigenetic changes, and other events leading to the formation of 
cancer. In case the targets of the miRNAs are essential to the survival of the cancer phe-
notype, downregulation of a gene with a specific miRNA could lead to a potential cure, 
or to discovery of a biomarker for cancer treatment or detection. (Croce 2009.) 
 
MicroRNA-32 is a miRNA that is located on chromosome 9 (9q31.3) and consists of 22 
nucleotides (Fang & Gao 2014).  Based on recent evidence, miR-32 was found to be 
potentially important in the development of castration-resistant prostate cancer. It has also 
been shown to be androgen-regulated and overexpressed in CRPC. (Waltering et al. 2011; 
Urbanucci et al. 2012; Jalava et al. 2012.)  A link to the reduced expression of B-cell 
translocation gene 2 (Btg2) – an anti-proliferative protein important for the correct func-
tion of the cell – has also been demonstrated in cell cultures. This evidence indicates that 
miR-32 a potential biomarker and a drug target for prostate cancer. (Jalava et al. 2012.) 
MicroRNA-32 has also been shown to downregulate the tumor suppressor gene Pten, 
post-transcriptionally, in cancers such as colorectal carcinoma, and to promote growth, 
migration, and invasion of the cancer (Wu et al. 2013).  
 
 
2.2.2 Proliferation marker Ki-67 
 
Ki-67 is a nuclear antigen, which can be used for evaluating cell proliferation. It is found 
during all phases of the cell cycle, except G0, making it an excellent marker for cancer. 
(Van der Kwast 2014.) The forkhead-associated domain (FHA domain) of Ki-67 enables 
it putatively to interact with phosphorylated proteins, linking it to an important protein 
network responsible for driving cell division cycles (Li et al. 2004). 
  
Expression of Ki-67 in cancer tissue is called the Ki-67 proliferation score, which can be 
quantified from immunohistochemically stained tissues. A high Ki-67 score in breast can-
cer is typically associated with poor prognosis and aggressive disease. (Urruticoechea et 
al. 2005.) Ki-67 is also one of the most studied biomarkers in prostate cancer. However, 
its prognostic value in cancer diagnosis still requires further research as prostate cancer 
is a highly heterogeneous disease. (Fisher et al. 2013.) Ki-67 expression is typically rare 
in normal prostate tissue where epithelial proliferation is uncommon. However, Ki-67 
expression can be seen, for example, in the ventral prostate and dorsolateral prostate in 
some mouse models. (Stanbrough et al. 2001.)  
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2.2.3 B-cell translocation gene 2 (BTG2) 
 
B-cell translocation gene 2 (BTG2) belongs to a family of antiproliferative proteins called 
BTG/Tob. Other members of the Btg family include Btg1, tob, tb2, Ana/Btg3, and Pc3k 
proteins. All of these proteins have similarities in their amino-terminal region with the 
Btg1 homology domain. BTG/Tob family proteins are all nuclear proteins, responsible 
for the regulation of several genes. (Kawamura-Tsuzuku et al. 2004.)  
 
Expression of Btg2 has been linked to important cell processes, such as cell cycle pro-
gression, differentiation, and apoptosis. It is a primary response gene, which is induced 
by different growth factors and tumor promoters. Also, Btg2 seems to be responsible for 
activating mRNA degradation, thus controlling gene expression. (Mauxion et al. 2008.) 
Based on recent evidence, Btg2 seems to have an important role in preventing carcino-
genesis and cancer.  In addition, Btg2 has been shown to be an important effector of p53 
signaling, which inhibits cellular transformation, suggesting that Btg2 is a tumor suppres-
sor gene. (Boiko et al. 2006.)  
 
According to recent evidence, Btg2 is a target of miR-32 in cell cultures. Btg2 expression 
is shown to be drastically reduced in CRCP and notably reduced in prostate cancer. There 
is evidence suggesting that Btg2 is associated with the aggressiveness of the disease, 
making it a possible biomarker for aggressive prostate cancer. (Jalava et al. 2012.) In 
addition, Btg2 is shown to be regulated by other miRNAs, such as miR-21 and miR-148a 
(Jalava et al. 2012; Coppola et al. 2013).  
 
Downregulation of Btg2 is suggested to be linked to the early events of the PCa progres-
sion. Loss of Btg2 leads to susceptibility of oxidative DNA damage, as Btg2 is involved 
in the pathway responsible for DNA damage repair, leading to further cellular damage 
and progression of the disease. In prostate tissue, Btg2 is mainly localized in the basal 
cells – the cells mainly responsible for prostatic proliferation. However, in prostatic le-
sions, Btg2 expression can be detected in most cell types, not just the basal cells. (Fi-
cazzola et al. 2001.) 
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2.2.4 Tumor suppressor gene PTEN  
 
Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene, located on chromo-
some 10 (10q23) (Celebi et al. 2000). In humans, The PTEN protein acts as a lipid phos-
phatase, responsible for the regulation of phosphatidylinositol 3-kinase (PI3K)/Akt-sig-
naling pathway, modulating cell cycle progression (Kanamori et al. 2001; Ohigashi et al. 
2005). Loss of PTEN is observed in many primary tumors, including tumors of the pros-
tate, and in up to 60% of metastases, cell lines, and xenografts (Hermans et al. 2004). 
Recently, it was found that loss of PTEN is an early event in the development of prostate 
cancer. Loss of PTEN is also associated with prostate cancer recurrence and poor prog-
nosis. (Yoshimoto et al. 2006; Yoshimoto et al. 2007.) 
 
Several mouse phenotypes can be used to investigate Pten expression. Pten knockout 
mice have been created with the inactivation of Pten gene, causing a disease progression 
similar to humans. (Wang et al. 2003.) Mice with a homozygous deletion of Pten (Pten−/− 
or Pten null) aren’t viable, making them embryonic lethal (Di Cristofano et al. 1998). 
Pten heterozygous (Pten+/−) mice are prone to develop neoplastic lesions in several or-
gans, including the prostate. PIN lesions are mainly detected in the dorsolateral prostate 
and anterior prostate, but not the ventral prostate. However, even with the development 
of PIN, Pten+/− mice generally do not progress to adenocarcinoma. (Blando et al. 2009.)  
 
Mice with a prostate-specific homozygous deletion of Pten, however, are linked to ad-
vanced disease and metastasis. The difference between these phenotypes is seen mainly 
in the timing of the disease development and progression. A conditional, homozygous 
deletion of Pten can significantly shorten the time required for the formation of PIN from 
8–10 months (heterozygous) to 1.5 months (homozygous). In wild type prostates, Pten 
expression can be seen in the nuclear and cytoplasmic compartments. A low level of ex-
pression is also seen in the prostatic epithelial cells and the stromal cells near the prostatic 
acini. (Wang et al. 2003.) 
 
 
 
 
  
17 
 
2.3 Methods for histological analysis 
 
 
2.3.1 Anatomy and histology of mouse prostate 
 
Human prostate is a distinct, lobular structure, surrounding the urethra. In comparison, 
the mouse prostate consists of multiple lobes that can be divided into anterior (AP), dorso-
lateral (DLP), and ventral prostates (VP). Dorsolateral prostate can be further divided into 
lateral prostate (LP) and dorsal prostate (DP). The lobes are separated by a thin mesothe-
lial-lined capsule. The lobes themselves consist of multiple ducts and tubules, surrounded 
by a dense fibromuscular stroma. Of all the prostate lobes, dorsolateral prostate is said to 
resemble the human prostate best. (Shappell et al. 2004.) For histological analysis, the 
prostates are collected from euthanized mice by following strict guidelines for the welfare 
and use of animals in cancer research (Workman et al. 2010). Figure 4 illustrates an H&E 
stained mouse prostate and surrounding structures. 
 
 
FIGURE 4. H&E stained overview of a PAXgene-fixed paraffin embedded mouse pros-
tate (Image: Leena Latonen, modified)  
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With histological examination of the anterior prostate (AP), a complex luminal structure 
can be observed. AP is located in close proximity to the seminal vesicles. Frequent mu-
cosal folding inside the gland is typical. Epithelial cells in the AP grow in a more cubical 
and columnar shape with central nuclei, and barely visible – or small nucleoli. Eosino-
philic granular cytoplasm is also observed. (Shappell et al. 2004.)   
 
The dorsal and lateral prostates are usually combined together as the dorstolateral pros-
tate. However, they are quite distinctive when compared histologically. The mouse dorsal 
prostate (DP) is typically surrounded by columnar, and stratified or tufting epithelium. 
The epithelium is usually thinly layered, and no clear mucosal folding is observed. The 
secretory cells of DP also have a slightly eosinophilic granular cytoplasm, and the gland 
secretions are homogenous and eosinophilic. Shape of the nuclei and nucleoli is similar 
to AP. In comparison, the lateral prostate (LP) has more flat, luminal edges, no clear in-
folding, and a wide luminal space, containing eosinophilic secretions. However, the DP 
has an increasingly large amount of eosinophilic secretions compared to LP.  (Shappell 
et al. 2004.)  
 
The ventral prostate (VP) has flat, luminal borders, and clear epithelial tufting and in-
folding. It is typically surrounded by a thin, fibromuscular stroma. The luminal spaces of 
VP are typically filled with homogenous secretions. The nuclei and nucleoli of VP are 
also small, uniformed, and located basally. When compared to the DP, the nuclei are 
typically more centered, and are found in a single-layered shape. (Shappell et al. 2004.) 
 
 
2.3.2 Tissue preparation in histology 
 
Histological sample preparation can be divided into four basic steps: fixation, processing, 
embedding, and sectioning. In fixation, a tissue sample is removed from its original in 
vivo environment, and quickly immersed in a fixative, in order to halt natural degenera-
tion of the tissue after death. Tissue degeneration is typically caused by hypoxia, lysoso-
mal enzymes, and putrefactive changes, which all occur in the tissue after death. (Ren-
shaw 2006, 47–48.) Multiple factors, such as hydrogen ion concentration, temperature, 
penetration, osmolality, concentration, and duration affect the fixation process. In order 
to retain the original structures, close to neutral pH is needed, as changes in pH may affect 
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biological systems. Penetration of the fixatives can also affect tissue staining: thin and 
small tissue samples are necessary for proper diffusion of fixatives. Poor fixation can also 
be caused by hypertonic solutions, which shrink the tissue – or hypotonic solutions, which 
cause the tissue to swell. (Hopwood 2002, 69–71.) Especially 10% neutral-buffered for-
malin is commonly used in histology as a chemical fixative (Sato et al. 2014). 
     
In addition to formalin fixation, other methods, such as PAXgene fixation, have gained 
popularity recently. PAXgene fixation is an alcohol-based method, where a 2-reagent 
system prevents cross-linking and degradation of the tissue. According to recent evi-
dence, PAXgene fixation gives comparable results to formalin fixation when used in both 
in situ hybridization and immunohistochemistry. However, in some cases, the results can 
be better with immunohistochemistry. Slight differences in tissue morphology can be ob-
served when compared to traditional formalin-fixed paraffin embedded (FFPE) tissues. 
(Kap et al. 2011.) 
 
Fixatives are usually water-based, thus a process is needed where the tissue is dehydrated, 
in order to allow impregnation of paraffin wax. The aim of dehydration is to remove all 
residuals of water-soluble fixatives, usually with a raising ethanol gradient. Next, the tis-
sue sample is treated with a clearing agent, such as xylene, toluene, or chloroform. The 
clearing agent causes the tissue to become translucent, improving the following step of 
paraffin wax impregnation. Paraffin wax is a mixture of different hydrocarbons with a 
varying melting point of 40–70 °C. (Anderson & Bancroft 2002, 85–90.) Next, the tissue 
is embedded in paraffin, cast into a mold of specific size, and promptly cooled on a cold 
plate. After solidification, the mold is removed and the tissue block is ready for sectioning 
with a microtome. (Anderson & Bancroft 2002, 89.)  
 
A microtome is an instrument that can be used for sectioning paraffin embedded tissue 
samples. They can repeatedly cut thin sections of paraffin with a steel knife or a blade. 
The sections are usually 5–15 μm thick. (Ross & Pawlina 2011, 2.) Several types of mi-
crotomes are available, but the most common ones are rotary microtomes and sliding 
microtomes (Anderson & Bancroft 2002, 86–90). After successful sectioning, the tissue 
is fixed to a microscope slide in a thermostatically controlled water bath with a tempera-
ture of about 10 °C below the melting point of the paraffin wax. The water bath ensures 
the sections are properly even, thus ensuring a proper morphology for analysis. The use 
of a proper section adhesive, such as poly-L-lysine or 3-aminopropyltriethoxysilane, is 
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necessary in order to ensure strong retention of the tissue to the slide. (Anderson & Ban-
croft 2002, 95–96.) However, there are commercially available products, such as the Su-
perFrost® Plus slides that require no special adhesives because of their electrostatical 
coating. After the treatment, the slides are shortly heat-treated in order to allow the sur-
rounding paraffin to melt. Heat-treatment is then followed by different histological stain-
ing methods, such as the basic hematoxylin & eosin staining method. (Anderson & Ban-
croft 2002, 97; Ross & Pawlina 2011, 2.) 
 
 
2.3.3 Hematoxylin & eosin staining 
 
Hematoxylin & eosin (H&E) staining is by far the most common basic staining method 
in histology. Hematoxylin is a component that stains the cell nuclei blue/black and gives 
a good detail of the intra-nuclear space. Eosin is responsible for staining cell cytoplasm 
and connective tissue fibers in different intensities of pink, orange, and red. (Wilson & 
Gamble 2002, 125.) However, H&E staining has its faults, as it does not display important 
structural components, such as elastic material, reticular fibers, certain membranes, and 
lipids. For staining these components, other methods must be utilized. (Ross & Pawlina 
2011, 3.)  
 
A tissue sample, which has been embedded in paraffin, sectioned, placed on a slide and 
dried in an oven, can be subjected to H&E staining. The slides are immersed in a series 
of solutions in order to hydrate the tissue. This includes xylene, alcohol, and water. Proper 
hydration for the slides is essential in order to give the cells affinity for the dyes. The 
slides are first stained with hematoxylin which stains the nucleus, and next, with eosin 
which acts as a counterstain. After rinsing in water, the slides are immersed in water, 
alcohol, and xylene in order to dehydrate the slides. However, if using a water-soluble 
mounting medium, the previous process can be excluded. Last, a coverslip can be attached 
to the slides, with the help of a mounting medium, enabling further histological analysis. 
(Sigma-Aldrich 2002.) 
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2.3.4 MicroRNA in situ hybridization  
 
In situ hybridization is a technique that allows the detection of a specific nucleic acid 
sequence in its cellular environment. The technique can be utilized on basic formalin-
fixed and paraffin embedded (FFPE) samples. The tissue sample is first pre-treated with 
proteinase-K to unmask the targeted nucleic acid sequence, and then hybridized with a 
complementary nucleic acid probe. A label is attached to the probe, which makes it pos-
sible to visualize the target sequence by light microscopy. (Jones 2002, 555.) MicroRNA 
in situ hybridization (miRNA ISH) is a technique that focuses on the determination of 
miRNA expression at a cellular level (Nielsen 2012, 67).  
 
Implementation of the miRNA ISH technique has been found to be relatively challenging 
in a laboratory setting due to the complexity of the process. Typically, ISH protocols use 
either DNA or RNA probes, depending on the focus of the analysis. However, the probes 
used in miRNA ISH are LNA:DNA chimeric probes, such as the commercial LNA™ 
probes, which significantly shorten the process to less than 20 steps. (Nielsen 2012, 67–
68.) LNA probes are modified DNA probes that contain locked nucleic acid (LNA) resi-
dues – a new class of bicyclic RNA analogs that have a higher-than-normal affinity to 
their complementary targets. LNA probes increase the thermal stability of the formed 
hybrids. (Thomsen et al. 2005.)   
 
First, the FFPE slides are deparaffinized in xylene and ethanol solutions in order to re-
move excess paraffin from the slides. Additionally, other agents, such as hexane, can be 
used for deparaffinization. Next, nucleic acid sequences are unmasked. As formaldehyde 
based fixatives mask nucleic acid sequences, the addition of proteinase-K is essential for 
successful miRNA ISH staining. Proteinase-K digests any nucleases present in the tissue 
sample, guarding against nucleic acid degradation. It is essential to optimize the protein-
ase-K concentration in order to have optimal nucleic acid unmasking. (Jones 2002, 564–
565.) The slides can then be dehydrated with ethanol to prepare for the hybridization 
(Nielsen 2012, 72).   
  
Conventional formaldehyde fixation has been shown to cause significant miRNA loss. 
To prevent the loss of miRNAs from the tissue section, additional fixation with 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide (EDC) can be used. EDC has been shown to 
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irreversibly fix the miRNA at its 5’phosphate, preventing significant miRNA loss during 
in situ hybridization. (Pena et al. 2009.) 
 
Optimization of the hybridization step is also important. The aim is to avoid non-specific 
interaction with other nucleic acids, and to maximize the reaction of the probe and the 
target sequence. First, the target sequence must be rendered single-stranded. The slides 
are placed in a hybridization chamber with strictly-controlled temperature and time. Usu-
ally temperatures of 25°C below the melting point are suitable. Variations in the temper-
ature can influence the success of the annealing process, and lead to poor signal. (Jones 
2002, 565–566.) The LNA™ probes are usually double-digoxigenin (DIG) labeled for 
chromogenic detection by light microscopy (Nielsen 2012, 69).  
 
For reliable results, controls must be used for the miRNA ISH. Typically, a positive con-
trol and a control with no hybridization are included. The positive control contains a target 
sequence that is similar to the target probes. The purpose of the positive control is to 
verify the overall performance of the used technique and the specificity of the acquired 
signal. The no-hybridization control lacks a LNA™ probe, thus providing information on 
any non-specific interaction of other agents used in the analysis. (Jones 2012, 567.) A 
popular positive control for in situ hybridization is the small nuclear RNA (snRNA) U6, 
localized in the nucleoli. U6 is essential for correct pre-mRNA splicing. (Gerbi & Lange 
2002.) Scrambled DNA – a probe without the target sequence – can be used as a negative 
control, as it only causes non-specific staining (Exiqon 2011, 27). 
 
After the hybridization, the slides are subjected to stringent washing steps, where the hy-
bridization is halted. Proper duration of the washing steps is important, as insufficient 
washing can cause high background staining. (Exiqon 2011, 28.) After stringent washing 
steps, the slides are incubated in a blocking solution. The blocking solution is used to 
reduce non-specific binding of the hybridization probe. Next, alkaline phosphatase-con-
jugated sheep anti-DIG is added. Anti-DIG-AP binds specifically to the double-DIG-la-
beled probe. After washes, a substrate solution, such as the nitro blue tetrazolium/5-
bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) substrate reagent, is added. Addition 
of the substrate makes the miRNA expression visible by light microscopy, as a blue end-
product is formed. The substrate is sensitive to light during development, so protection 
from all light sources is necessary. In addition, Nuclear Fast Red counterstain can be 
added to ease the recognition of surrounding structures near the miRNA expression site. 
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After washes and a second dehydration, the slides are mounted with a suitable mounting 
medium, and a coverslip is attached for observation by light microscopy. (Nielsen 2012, 
72–73.) Figure 5 summarizes the possible steps of a miRNA ISH technique. Washes with 
PBS are not shown in the figure, as they are mandatory after each step.   
 
 
FIGURE 5. Typical steps in a miRNA ISH protocol  
 
 
2.3.5 Immunohistochemistry 
 
Immunohistochemistry (IHC) is a technique for visualizing the specific immunologic re-
action of an antigen and an antibody. It can be utilized, in addition to research purposes, 
in the diagnostics of clinical pathology. Typical uses of IHC include phenotyping, exam-
ination of morphology, and clinical diagnoses. It is especially important for studying the 
location of different biomarkers in tissues, for example in cancer research. (Miller 2002, 
421–423.)  
 
Antibodies are a group of proteins called immunoglobulins (Ig). Immunoglobulins are 
found in plasma or serum, and they are divided into 5 major categories: IgG, IgA, IgM, 
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IgD, and IgE. They are formed by the immune system after B lymphocytes recognize 
foreign antigens and transform into plasma cells. Immunoglubulins IgG and IgM are the 
most frequently used antibodies in immunohistochemistry. Immunoglobulins have a com-
mon structure: they are formed by two light and heavy polypeptide chains, linked together 
with disulfide bonds. The terminal regions in these molecules have varying amino acid 
sequences, also known as variable domains. These variable domains are the reason anti-
bodies can bind to specific antigens, as certain amino acid sequences bind specifically on 
epitopes of the antigens. Epitopes, or antigenic determinant groups, are a small group of 
amino acids or monosaccharide units that are found on the topographical regions of the 
antigens. Antigens themselves can be either proteins, carbohydrates, or lipid molecules. 
(Miller 2002, 423–424.)  
 
Antibodies can be produced either as poly- or monoclonal. Polyclonal antibodies are pro-
duced in animals that are immunized with a specific molecule – an immunogen – con-
taining the desired antigen. As a result, the immune system of the animal produces anti-
bodies to counter the foreign antigens. The antibodies can be harvested by bleeding the 
animal and collecting the serum. The plasma cells of the animal produce antibodies that 
have a slightly different affinity towards other epitopes of the immunogen, making the 
antibodies polyclonal. Due to the polyclonal nature of the antibodies, there can be signif-
icant variability in different batches when compared to monoclonal antibodies. (Miller 
2002, 424.) 
  
Monoclonal antibodies, unlike polyclonal antibodies, are produced in a single cell line 
using hybridoma cell lines. The technique takes advantage of plasma cells for the produc-
tion of specific antibodies, and the immortality of a neoplastic myeloma cell line. These 
functions are combined to produce a hybridoma which has the combined abilities of both 
cell types. Due to the limitless growth of the hybridoma cell line, the cells can be cloned 
and grown in cell culture in almost unlimited numbers. With common screening tech-
niques, the antibodies can be produced without the cross-reactivity that can be found in 
polyclonal antibodies. The hybridoma cell lines will produce pure, specific antibodies in 
a constant supply, which can be especially useful in immunohistochemistry. (Miller 2002, 
424.)  
 
To visualize the binding of an antibody and an antigen, a label must be used. Especially 
enzymes are widely used in immunohistochemistry. When enzymes are incubated with a 
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chromogen, a colored end-product is produced that can be visualized by light microscopy. 
Horseradis peroxidase (HRP) and calf intestinal alkaline phosphatase (AP) are widely 
used. When HRP is combined with 3,3´-diaminobenzine tetrahydrochloride (DAB), a sta-
ble, dark brown end-product is formed. (Miller 2002, 424–425.) Alkaline phosphatase, 
on the other hand, produces an insoluble black-purple end-product when incubated with 
a combination of nitro-blue tetrazolium chloride (NBT) and 5-bromo-4-chloro-3'-indoly-
phosphate p-toluidine salt (BCIP) (Thermo Scientific 2014).  
 
Conjugation of a label to an antibody can be performed with two distinct techniques: 
traditional direct technique and indirect technique. In the direct technique, the primary 
antibody is conjugated directly to the label. Utilization of the direct technique is relatively 
simple, as only one application of an antibody is needed, along with the substrate solution. 
In the indirect technique, an unconjugated primary antibody is applied first, followed by 
a labeled, secondary antibody. Application of a secondary antibody increases signal sen-
sitivity due to increased interactions between the two antibodies, increasing the amount 
of substrate attached to the sample. (Miller 2002, 426–427.)  
 
In addition to basic methods, several other modified techniques with significantly higher 
sensitivity are available. For example, the avidin–biotin technique (ABT) has been found 
to have high sensitivity. This technique relies on the high affinity of the glycoprotein 
avidin for biotin. Multiple biotin molecules can be attached to a single antibody, followed 
by the conjugation of a labeled avidin, leading to a heightened signal. (Miller 2002, 427.)  
 
Recently, more advanced commercial techniques have surfaced as well. For example, 
certain polymer-based techniques, such as the EnVision™ FLEX+ system (Dako) or the 
N-Histofine® Simple Stain MAX PO (multi) detection reagent (Nichirei Biosciences), 
offer a universal reagent that can be used to detect almost any tissue-bound primary anti-
body, regardless of the origin (rabbit or mouse). Both of these methods consist of a poly-
mer backbone, on which the antibodies and enzymes can attach to. (Key 2009, 58–59.) 
 
Samples in immunohistochemistry are typically either frozen sections or FFPE sections. 
After proper fixation and sample preparation, the samples are first subjected to deparaf-
finization with solvents, such as xylene or n-hexane.  Excess traces of the solvents are 
then removed by rehydrating the sample with ethanol. As tissue fixation and processing 
may change the structure of the antigen epitopes, the samples are subjected to antigen 
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retrieval techniques, where the original antigen epitopes are restored. This can be 
achieved with different proteolytic enzymes, heat-mediated techniques or a combination 
of these methods. (Miller 2002, 435–440.) 
 
Traditional formalin fixation alters the three-dimensional structure of several tissue pro-
teins, thus making the demasking of epitopes important for a successful IHC staining. 
Heat-induced epitope retrieval (HIER) is a commonly used method for the demasking of 
epitopes. HIER can be achieved with many techniques, such as the conventional water 
bath heating, pressure cooker heating or microwave oven heating. For example with water 
bath heating, the sample slides are first placed in a buffer (citrate buffer pH 6 or Tris-
EDTA buffer pH 9), which is then heated to around + 97 °C for 20 minutes. After cooling, 
the samples can be directly subjected to immunohistochemical staining. (Kumar & Rud-
beck 2009, 51–52.) 
 
Next, the samples are subjected to a blocking technique, where unspecific background 
staining is prevented. Blocking is usually performed with a buffer containing an immu-
noglobulin that does not interact with the primary antiserum. The blocking agent is pro-
duced in the same species as the primary antibody. Background staining is typically 
caused by hydrophobic and electrostatic forces in certain locations of tissues. (Miller 
2002, 435–440.) 
 
After successful blocking, IHC staining can be performed. For example, in the avidin–
biotin technique, samples are first incubated in a primary antibody, followed by a bioti-
nylated secondary antibody. Next, a streptavidin-enzyme conjugate can be used, followed 
by a substrate-chromogen mixture. All steps in the staining process are followed by 
washes in order to remove trace amounts of the previous solution. (Thermo Scientific 
2014.) After staining, the slides are typically counterstained with hematoxylin to improve 
morphological recognition. Counterstaining is followed by dehydration with ethanol, fol-
lowed by a clearing agent, and finally, with the addition of a coverslip with a proper 
mounting reagent. (Miller 2002, 453–454.) Figure 6 summarizes a simplified version of 
a standard immunohistochemical staining process.  
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FIGURE 6. A simplified version of the steps in a standard IHC staining process  
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3 AIM OF THE STUDY 
 
 
The objective of the thesis is to study the expression of several putative biomarkers in 
transgenic mouse prostate tissue. This thesis will help improve further histopathological 
examination of prostate cancer for the Molecular Biology of Prostate Cancer group in 
hopes of finding putative biomarkers and treatment options for prostate cancer (PCa) and 
castration-resistant prostate cancer (CRPC). 
 
The purpose of the thesis is to establish protocols for the in situ hybridization of miR-32 
and the immunohistochemistry of Ki-67, Btg2, and Pten – and to study the expression of 
these putative biomarkers in PAXgene-fixed paraffin embedded (PFPE) or formalin-fixed 
paraffin embedded (FFPE) mouse prostate tissue. The establishment of the in situ hybrid-
ization protocol for miR-32 will help evaluate the success of the transgenic mouse line, 
previously established by the research group, expressing miR-32 specifically in the pros-
tate. By establishing protocols for the immunohistochemistry of Ki-67, Btg2, and Pten, it 
is possible to investigate the expression of these genes in mouse lines with confirmed 
prostatic lesions in order to further evaluate their role in prostate carcinogenesis, and in 
the formation of castration resistance. 
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4 MATERIALS AND METHODS 
 
 
4.1 In situ hybridization of miR-32 
 
 
4.1.1 Sample preparation 
 
For in situ hybridization, suitable mouse prostate tissue samples were chosen. Both for-
malin-fixed paraffin embedded (FFPE) samples and PAXgene-fixed paraffin embedded 
(PFPE) samples were tested. The prostates were obtained, before the project, from mice 
by separating the prostate, seminal vesicles, and the bladder from the surrounding tissues. 
The obtained prostates were stored in a container with 10% formalin or the commercial 
PAXgene fixative. After fixation, the tissue samples were prepared for processing and 
embedding. Shandon Citadel 2000 Tissue Processor was used for automated tissue pro-
cessing. The protocol for both FFPE and PFPE processing is shown in table 1. 
 
TABLE 1. The protocol for FFPE and PFPE sample fixation 
Step Substance Duration 
1 Formalin/PAXgene - 
2 70% EtOH 2 h 
3 96% EtOH 1.5 h 
4 96% EtOH 1 h 
5 Abs. EtOH 1.5 h 
6 Abs. EtOH 1.5 h 
7 Abs. EtOH 1.5 h 
8 Xylene 1.5 h 
9 Xylene 1.5 h 
10 Xylene 1.5 h 
11 Paraffin (58 °C) 1.5 h 
12 Paraffin (58 °C) 1.5–4 h 
 
Processed tissue samples were then embedded in paraffin. Sakura Tissue-Tek TEC em-
bedding center was used for tissue embedding. The prostate sample was first placed in a 
Tissue-Tek® mold system in a fixed orientation. 60 °C paraffin was poured in the mold 
which was placed on a cold plate for a few seconds. A Tissue-Tek® cassette was placed 
on top of the tissue and paraffin was added until the mold was completely immersed. The 
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mold was then placed on a cold plate until the paraffin wax solidified. The tissue blocks 
were stored at room temperature until sectioning. 
 
Both FFPE and PFPE tissue blocks were placed on a + 4 °C cold plate for 15 minutes 
before sectioning. All surfaces were wiped with RNaseZAP™ solution to remove possi-
ble RNAse contaminations. Dry-heat treated glass equipment and DEPC-treated water 
were used. Leica SM2010 R microtome was used to cut suitable sections from the tissue 
blocks. S35 disposable microtome blades were utilized to cut 8 – 10 µm thick sections 
from both FFPE and PFPE samples. The sections were first placed in DEPC-treated water 
at room temperature, and then attached to SuperFrost™ Plus microscope slides. Next, the 
slides were placed shortly in + 52 °C water bath to straighten the tissue section. After 30 
minutes of drying at room temperature, the samples were placed in an oven at + 62 °C for 
45 minutes. After the heat treatment, the slides were stored at + 4 °C overnight for in situ 
hybridization.  
 
 
4.1.2 Establishment of in situ hybridization protocol  
 
A total of 6 samples were used for the protocol establishment. The samples were either 
PAXgene- or formalin-fixed. Wild type prostates were used. During the establishment, 
only U6 and Scrambled DNA probes were used, as suitable conditions for the protocol 
had to be established first. In addition, one PAXgene-fixed sample and one formalin-fixed 
sample was subjected to H&E staining for better morphological examination.  
 
The previously prepared tissue sections were brought to room temperature from the + 4 
°C cold room. First, deparaffinization was performed in order to remove excess paraffin 
around the tissue. Coplin jars, sterilized with dry-heat (180 °C), were used throughout the 
entire process. All surfaces, during in situ hybridization, were first treated with 
RNAseZap™ solution to remove possible RNAse contaminations. The slides were im-
mersed in n-hexane, 100% ethanol, and 1X phosphate-buffered saline (PBS), sequen-
tially, by placing them in Coplin jars for indicated times (table 2).  
 
 
 
 
31 
 
TABLE 2. The protocol for deparaffinization 
Step Reagent Duration 
1 n-hexane 4 min 
2 n-hexane 4 min 
3 100% EtOH 2 min 
4 1X PBS 5 min 
5 1X PBS 5 min 
 
After deparaffinization, the slides were prepared for deproteinization. 2.5 µg/ml of pro-
teinase-K in proteinase-K buffer was used. Proteinase-K demasks the microRNAs found 
in the tissue sample by digesting proteins and contaminations, allowing the probe to hy-
bridize with the target microRNA sequence (Exiqon 2011, 10). The slides were incubated 
in 300 µl of proteinase-K and immersed, sequentially, in PBS, 4% paraformaldehyde 
(PFA), 0.2% glycine and last, in PBS (table 3). The exact content of the proteinase-K 
buffer, 4% paraformaldehyde, and 0.2% glycine is listed in appendix 1. 
 
TABLE 3. The protocol for deproteinization 
Step Reagent Duration 
1 Proteinase-K 20 min 
2 1X PBS 5 min 
3 1X PBS 5 min 
4 4% PFA 10 min 
5 0.2% glycine 5 min 
6 1X PBS 5 min 
7 1X PBS 5 min 
 
After washes with PBS, the slides were incubated in 75 ml of freshly prepared imidazole 
buffer. The tissues were then circled with a PAP pen, which creates a hydrophobic coating 
around the tissue, improving the retention of liquid near the tissue. At this point, a addi-
tional fixation with EDC was possible. However, during the protocol establishment, EDC 
fixation was not attempted. The slides were washed with glycine and PBS, respectively. 
Table 4 shows the duration of the incubations and the concentrations. The exact content 
of both imidazole buffer and EDC solution is listed in appendix 1. 
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TABLE 4. The protocol for EDC fixation 
Step Reagent Duration 
1 Imidazole buffer 10 min 
2 Imidazole buffer 10 min 
3 EDC solution 60 min 
4 0.2% glycine 5 min 
5 1X PBS 5 min 
6 1X PBS 5 min 
 
Next, hybridization was performed. 5’-DIG-labeled U6 LNA™ probe (5'-CACGAATTT-
GCGTGTCATCCTT-3') from Exiqon was used as a positive control. 5’-3’-DIG-labeled 
scrambled DNA LNA™ probe (5’- GTGTAACACGTCTATACGCCCA-3’) from Ex-
iqon was used as a negative control. 500 µl of prehybridization buffer was added to each 
slide at room temperature for 15 minutes. Probes were then denatured at + 90 °C for 4 
minutes. 1:50 dilutions were prepared of each probe by diluting with the hybridization 
buffer. 200 ul of hybridization mix was added on each slide, and the slides were covered 
with a piece of parafilm, wiped with the RNAseZap™ solution. The slides were then 
placed in StatSpin® ThermoBrite Denaturation and Hybridization System for 21 hours at 
the chosen temperature (+ 37 °C). The exact details of both U6 and Scrambled DNA 
probes, prehybridization buffer, and hybridization buffer is listed in appendix 1. 
 
The next morning, the slides were subjected to stringent washes at the hybridization tem-
perature (+ 37 °C). The slides were immersed in a mix of saline-sodium citrate (SSC) and 
formamide in Coplin jars. The Coplin jars were placed in a water bath, which was heated 
to + 37 °C. The slides were rinsed in 0.2X SSC at room temperature to remove trace 
amounts of formamide, and washed with 1X PBS 0.1% Tween-20. The concentrations 
and duration of the washes are listed in table 5. The exact details of all the stringent wash 
buffers is listed in appendix 1. 
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TABLE 5. The protocol for the stringent washes  
Step Reagent Duration 
1 1st Stringent wash buffer 15 min 
2 2nd Stringent wash buffer 30 min 
3 3rd Stringent wash buffer 45 min 
4 0.2X SSC 5 min 
5 1X PBS, 0.1% Tween-20 1 min 
 
After the stringent washes, the slides were placed in Shandon Slide Racks for the staining 
process. The staining process consisted of multiple phases: incubation in anti-DIG-HRP 
(1:800 dilution), DIG amplification working solution (1:50 dilution), anti-DIG-AP (1:800 
dilution), NBT/BCIP substrate solution (1:50 dilution), and KTBT buffer. Incubations 
were performed with 200 µl of each reagent. Washes in between the staining steps were 
performed using 1X PBS 0.1% Tween-20. The incubation with NBT/BCIP substrate was 
performed at + 30 °C, protected from all light sources. The other staining reagents were 
added, and washing steps were performed at room temperature. Table 6 illustrates the 
used solutions and the duration of the incubation periods during the staining process. The 
exact content of anti-DIG-HRP, DIG amplification working solution, anti-DIG-AP, 
NBT/BCIP substrate solution, and KTBT buffer is listed in appendix 1.  
 
TABLE 6. The protocol for the staining process   
Step Reagent Duration 
1 1X blocking solution 15 min 
2 Anti-DIG-HRP 1:800 30 min 
3 1X PBS, 0.1% Tween-20 3X 5 min 
4 DIG Amplification solution 1:50 10 min 
5 1X PBS, 0.1% Tween-20 3X 5 min 
6 Anti-DIG-AP 1:800 60 min 
7 1X PBS, 0.1% Tween-20 3X 3 min 
8 NBT/BCIP substrate 2 h 
9 KTBT buffer 2X 5 min 
10 DEPC-treated water 1 min 
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Next, the slides were subjected to dehydration and mounting. The slides were briefly im-
mersed in an ascending ethanol gradient. After air-drying, 3 drops of Eukitt® quick-hard-
ening mounting medium was added, and a coverslip was attached to the slide. The slides 
were then left at room temperature, and subjected to analysis by light microscopy the 
following morning. The exact process of dehydration is listed in table 7. 
 
TABLE 7. The protocol for dehydration    
Step Reagent Duration/immersion 
1 70% EtOH 10 times 
2 70% EtOH 1 min 
3 96% EtOH 10 times 
4 96% EtOH 1 min 
5 100% EtOH 10 times 
6 100% EtOH 1 min 
 
 
4.1.3 In situ hybridization of miR-32 and protocol optimization 
 
The in situ hybridization of miR-32 was performed by following the previously estab-
lished protocol – with only minor modifications along the way. A total of 24 samples in 
three separate attempts were subjected to in situ hybridization during the optimization. 
Only PAXgene-fixed samples were used, as the expression of the test probes was deemed 
better on the PAXgene-fixed samples compared to formalin-fixed samples. U6 probes 
and scrambled DNA probes were used during all attempts in order to ensure the specific-
ity of miR-32 expression. Conditions, such as the proteinase-K concentration, probe di-
lution ratio, EDC fixation, and sample thickness were adjusted during the project. The 
samples subjected to in situ hybridization are listed in table 8.  
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TABLE 8. The samples used during the optimization of in situ hybridization  
Samples Type Fixation Probe/process 
3 Wild type PAXgene U6 
3 Wild type PAXgene Scrambled DNA 
3 Wild type PAXgene miR-32 
3 Wild type PAXgene H&E staining 
3 Transgenic PAXgene U6 
3 Transgenic PAXgene Scrambled DNA 
3 Transgenic PAXgene miR-32 
3 Transgenic PAXgene H&E staining 
 
5’-3’-DIG-labeled miR-32 LNA™ detection probe (5’-GCAACTTAGTAATGTG-
CAATA-3’) by Exiqon was used as the sample probe for miR-32 detection. The U6 and 
Scrambled DNA probes remained the same as in the protocol establishment. Proteinase-
K concentration varied between 2.5–10 µg/ml during all the attempts. Probe dilutions of 
either 1:500 or 1:1000 were used. The hybridization time varied between 16 to 21 hours. 
However, the hybridization temperature (+ 37 °C) remained the same throughout the op-
timization attempts. An additional 60-minute EDC fixation was attempted twice during 
the optimization. Thickness of the tissue samples varied from 8 µm to 10 µm. In addition 
to in situ hybridization, a total of six samples were subjected to H&E staining for better 
morphological examination, as the in situ hybridization samples were not counterstained.  
 
 
4.1.4 Hematoxylin & eosin staining  
 
In addition to in situ hybridization, one slide of each type was subjected to H&E staining. 
As counterstaining was not used during in situ hybridization, additional H&E staining 
was required for proper morphological analysis. The H&E stained sample was obtained 
from the same tissue block as the miR-32 sample, allowing almost identical morphologi-
cal comparison. After the 45-minute heat treatment, the slides were subjected to H&E 
staining. Sakura DRS-60 Autostainer was used to automate the staining process. The pro-
gram for automated H&E staining is listed in table 9. 
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TABLE 9. The program for the automated H&E staining process 
Step Solution Time 
1 n-hexane 3 min 
2 n-hexane 3 min 
3 Abs. EtOH 2 min 
4 Abs. EtOH 1 min 
5 96% EtOH 2 min 
6 70% EtOH 1 min 
7 dH2O 30 s 
8 Harris Hematoxylin 1:4 4 min 
9 H2O 7 min 
10 dH2O 40 s 
11 0.2% Eosin 2 min 
12 H2O 1 min 
13 dH2O 30 s 
14 96% EtOH 2 min 
15 96% EtOH 2 min 
16 Abs. EtOH 1 min 
17 Abs. EtOH 2 min 
18 Abs. EtOH 2 min 
 
After successful staining, the slides were immersed twice in xylene for 4 minutes. Next, 
Dako Coverslipper was used to automatically attach a coverslip to each microscope slide. 
DPX mounting medium (Sigma-Aldrich) was used to attach the coverslip. The slides 
were left at room temperature overnight until the mounting medium had solidified. The 
H&E stained slides were then subjected to morphological analysis, along with the sam-
ples from in situ hybridization, by light microscopy. 
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4.2 Immunohistochemistry of Ki-67, Btg2, and Pten 
 
 
4.2.1 Sample preparation 
 
For immunohistochemical staining, both PFPE and FFPE samples were used. The tissue 
processing and embedding were identical to in situ hybridization (table 1). The tissue 
blocks were first placed on a + 4 °C cold plate for 15 minutes before sectioning. S35 
disposable microtome blades were utilized to cut 5–8 µm thick sections. The sections 
were placed in a water bath at room temperature, attached to SuperFrost™ Plus micro-
scope slides, and placed shortly in + 52 °C water bath to straighten the tissue section. The 
slides were left at room temperature in an upwards position for 30–60 min to remove 
excess water. The slides were then placed in an oven at + 62 °C for either 2 hours or 
overnight. After the heat-treatment, the slides were ready for IHC staining.  
 
 
4.2.2 Establishment of IHC staining methods  
 
The first task of the immunohistochemical staining was to establish suitable conditions 
for the staining process. Several key conditions, such as the antibody dilution ratio and 
the type of the antibody were adjusted during the project. The IHC methods were estab-
lished for Ki-67, Btg2, and Pten. Most of the conditions remained the same throughout 
the testing of all three antibodies. A total of 20 samples were used for the method estab-
lishment: ten for Ki-67, five for Btg2 and five for Pten. 
 
The heat-treated slides were first subjected to deparaffinization. The slides were im-
mersed in n-hexane twice for 4 minutes and once in 100% ethanol for 2 minutes. After 
air-drying, the slides were subjected to heat-induced epitope retrieval (HIER). Lab Vi-
sion™ PT Module was used to automate the retrieval process. Tris-EDTA buffer solution 
(TE buffer) pH 9.0, containing 0.05% Tween-20 was first pre-heated to + 65 °C, and the 
previously deparaffinizated slides were placed in the buffer. The buffer was then heated 
to + 98 °C for 15 minutes. After cooling, the slides were placed in 1X TBS-Tween-20 
until staining. LabVision Autostainer 480 was used to automate the IHC process. Table 
10 details the program used for the staining process.  
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TABLE 10. The IHC staining program for LabVision Autostainer 480 
Step Solution/reagent Duration 
1 TBS Tween Wash 
2 Endogenous peroxidase blocking with 3% H2O2 5 min 
3 TBS Tween Wash 
4 Primary antibody 30 min 
5 TBS Tween Wash 2x 
6 Histofine Simple Stain MAX PO 30 min 
7 TBS Tween Wash 
8 TBS Tween Wash 
9 ImmPACT DAB 5 min 
10 TBS Tween Wash 2x 
11 TBS Tween Wash 
12 Mayer’s Hematoxylin 2 min 
13 TBS Tween Wash 
 
For the IHC staining of Ki-67, two different antibodies were tested: mouse (MM1) anti-
Ki67 (Leica Biosystems) and rabbit (SP6) anti-Ki67 (Thermo Scientific). The immuno-
histochemical staining of Pten was performed with anti-Pten (Cell Signaling Technology) 
and Btg2 with anti-Btg2 (Santa Cruz Biotechnology). Dilution ratios of 100, 200, 500, 
800, and 1000 were tested during the project. Antibody dilutions were made in Normal 
Antibody Diluent (Immunologic). All samples were cut from PFPE blocks (wild type). 
Secondary antibody labeling was performed with N-Histofine® Simple Stain MAX PO 
(multi) detection reagent (anti-mouse and anti-rabbit), developed by Nichirei Biosci-
ences. ImmPACT DAB Peroxidase (HRP) Substrate (Vector Laboratories) was used as 
the reaction substrate. The samples used for testing are listed in table 11. Exact detail of 
each antibody and reagent is listed in appendix 2. 
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TABLE 11. The samples for IHC dilution testing 
Sample Antibody Dilution 
Ki67-350wt-1 Ki-67 (MM1) 1:200 
Ki67-350wt-2 Ki-67 (MM1) 1:400 
Ki67-350wt-3 Ki-67 (MM1) 1:600 
Ki67-350wt-4 Ki-67 (MM1) 1:800 
Ki67-350wt-5 Ki-67 (MM1) 1:1000 
Ki67-350wt-6 Ki-67 (SP6) 1:100 
Ki67-350wt-7 Ki-67 (SP6) 1:200 
Ki67-350wt-8 Ki-67 (SP6) 1:500 
Ki67-350wt-9 Ki-67 (SP6) 1:800 
Ki67-350wt-10 Ki-67 (SP6) 1:1000 
Btg2-350wt-1 Btg2 1:100 
Btg2-350wt-2 Btg2 1:200 
Btg2-350wt-3 Btg2 1:500 
Btg2-350wt-4 Btg2 1:800 
Btg2-350wt-5 Btg2 1:1000 
Pten-350wt-1 Pten 1:100 
Pten-350wt-2 Pten 1:200 
Pten-350wt-3 Pten 1:500 
Pten-350wt-4 Pten 1:800 
Pten-350wt-5 Pten 1:1000 
 
After the run, the slides were placed in milliQ water. Dehydration was performed by im-
mersion in 70%, 96%, and 100% ethanol. The exact process is detailed in table 12. After 
dehydration, the slides were placed in xylene twice for 4 minutes. Dako Coverslipper was 
used to attach a coverslip on the slides. DPX mounting medium (Sigma-Aldrich) was 
used as a hardening agent. The slides were left to dry at room temperature until analysis 
by light microscopy.  
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TABLE 12. The dehydration process for Ki67, Btg2, and Pten 
Step Reagent Duration/Immersion 
1 70% EtOH 10x 
2 70% EtOH 1 min 
3 96% EtOH 10x 
4 96% EtOH 1 min 
5 100% EtOH 10x 
6 100% EtOH 5 min 
 
 
4.2.3 IHC staining of Ki-67, Btg2, and Pten 
 
A total of 14 samples were subjected to immunohistochemistry during the project: four 
samples for Ki-67, four for Btg2 and six for Pten. IHC staining was performed for both 
PFPE and FFPE samples. Both wild type (WT) and transgenic (TG) mouse tissue blocks 
were used for comparison. The samples were chosen from tissue blocks with close mor-
phological similarity to the miRNA ISH samples. For PAXgene-fixed samples of Pten, 
both homozygous (Pten+/+) and heterozygous (Pten+/-) mouse lines were analyzed. The 
exact details of the samples are listed in table 13. 
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TABLE 13. The IHC stained samples for Ki-67, Btg2, and Pten 
Sample Type Fixation Dilution 
Ki67-1 Wild type PAXgene 1:100 
Ki67-2 Transgenic PAXgene 1:100 
Ki67-3 Wild type Formalin 1:100 
Ki67-4 Transgenic Formalin 1:100 
Btg2-1 Wild type PAXgene 1:800 
Btg2-2 Transgenic PAXgene 1:800 
Btg2-3 Wild type Formalin 1:800 
Btg2-4 Transgenic Formalin 1:800 
Pten-1 Wild type/homozygote PAXgene 1:200 
Pten-2 Transgenic/homozygote PAXgene 1:200 
Pten-3 Wild type/heterozygote PAXgene 1:200 
Pten-4 Transgenic/heterozygote PAXgene 1:200 
Pten-5 Wild type Formalin 1:200 
Pten-6 Transgenic Formalin 1:200 
 
Suitable dilution ratios were determined during the establishment of the protocol. 1:100 
dilution was used for Ki-67, 1:800 dilution for Btg2, and 1:200 dilution for Pten. Antigen 
retrieval was performed with the HIER method, as established previously, by using Tris-
EDTA buffer 0.05% Tween-20 (pH 9). Rabbit (SP6) anti-Ki67 was used for the IHC of 
Ki-67, anti-Pten (Cell Signaling Technology) for Pten and anti-Btg2 (Santa Cruz Bio-
technology) for Btg2. The same secondary antibody (N-Histofine® Simple Stain MAX 
PO) and chromogen (ImmPACT DAB) were used for visualization. The IHC staining 
was performed with LabVision Autostainer 480 using the same program as listed in table 
10.  
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5 RESULTS 
 
 
5.1 In situ hybridization of miR-32 
 
 
5.1.1 Established conditions for the in situ hybridization 
 
The conditions for in situ hybridization were established with four separate attempts. The 
aim of the project was to establish a working method where the level of expression of 
miR-32 was sufficient for analysis – not to obtain the absolute optimal conditions. Perfect 
optimization of the method would have taken much longer than the time allotted for the 
project.  
 
At first, both FFPE and PFPE tissue samples were used. However, it was quickly noted 
that the expression of U6 (positive control) in PAXgene-fixed tissues was sufficient for 
analysis, thus making the inclusion of formalin-fixed samples unnecessary. The hybridi-
zation temperature of + 37 °C for 21 hours was found to be suitable. Proteinase-K con-
centration was found to be suitable for both U6 and miR-32 probes at 5.0 µg/ml. Probe 
dilution of 1:500, anti-DIG-AP of 1:800, anti-DIG-HRP of 1:800, NBT/BCIP substrate 
of 1:50 and DIG Amplification working solution of 1:50 were all found sufficient. EDC 
fixation was found to cause too much background staining, making it difficult to judge 
specificity. Sample thickness of 8 μm was used to obtain the best results. Sections with 
the thickness of 10 μm were found to have poor constancy with the staining: not all parts 
of the tissue were stained evenly. Table 14 illustrates the conditions that were used to 
obtain successful miR-32 expression. The exact list of reagents used for positive miR-32 
expression is listed in appendix 1.  
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TABLE 14. The conditions for the best miR-32 expression with in situ hybridization 
Condition Details 
Hybridization temperature 21 h at + 37 °C 
Proteinase-K concentration 5.0 µg/ml 
Probe dilution 1:500 
anti-DIG-AP dilution 1:800 
anti-DIG-HRP dilution 1:800 
NBT/BCIP substrate dilution 1:50 
DIG Amplification working solution 1:50 
EDC fixation No 
Sample thickness 8 μm 
 
 
5.1.2 Expression of miR-32 in transgenic mouse prostate tissue 
  
To investigate the expression of miR-32 in transgenic mouse prostate tissue, the results 
of in situ hybridization of both wild type (WT) and transgenic (TG) prostates were com-
pared. The obtained results are shown in figure 7 as a 40X magnification of the dorsolat-
eral prostate. The pictures were taken manually with the Olympus U-CMAD-2 camera 
system. Figures 7A–7D represent the staining of WT prostate and figures 7E–7H the TG 
prostate.  
 
Basic H&E staining of both WT and TG prostates is shown in figure 7A and 7E, respec-
tively, where morphology of the dorsolateral prostate can be seen. As seen in figure 7B 
and 7F, scrambled DNA probe shows minimal or no expression in both WT and TG pros-
tates. However, some unspecific staining can observed in the WT prostate. Intense U6 
expression can be observed in both WT and TG prostates, as seen in figures 7C and 7G. 
However, significant background staining can also be detected, especially in the TG pros-
tate. A low level of miR-32 expression can be clearly seen (figures 7D and 7H) in both 
WT and TG prostates when compared to the negative controls.  
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FIGURE 7. Results of the in situ hybridization. 40X magnification of the dorsolateral 
prostate. Picture taken with Olympus U-CMAD-2 camera. Results of both wild type (WT) 
and transgenic (TG) prostates are shown. (A) H&E staining of WT prostate. (B) Scram-
bled DNA staining of WT prostate. (C) U6 staining of WT prostate. (D) miR-32 staining 
of WT prostate. (E) H&E staining of TG prostate. (F) Scrambled DNA staining of TG 
prostate. (G) U6 staining of TG prostate. (H) miR-32 staining of TG prostate  
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5.2 Immunohistochemistry of Ki-67, Btg2, and Pten 
 
 
5.2.1 Expression of Ki-67 in transgenic mouse prostate tissue 
 
The expression of Ki-67 was investigated by comparing both WT and TG mouse pros-
tates. In addition, the differences in both PAXgene fixation and formalin fixation were 
compared. The obtained results are shown in figure 8 as a 20X magnification of the ven-
tral or dorsolateral prostate. The pictures were taken with the Olympus U-TV1X-2 camera 
system using the automated Objective Imaging Surveyor scanning program.  
 
Figure 8A represents the Ki-67 expression of the PAXgene-fixed WT prostate.  Figure 
8B show the expression of Ki-67 in the PAXgene-fixed TG prostate. The expression of 
Ki-67 in formalin-fixed prostate is seen in figures 8C (WT) and 8D (TG). The brown 
staining of the nuclei is a representation of the Ki-67 expression in all the figures. The 
Ki-67 expression is marked with a black arrow in the figures. The blue-colored nuclei 
show no expression of Ki-67, as the blue color is a product of the Mayer’s hematoxylin 
counterstaining.   
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FIGURE 8. Results of the Ki-67 immunohistochemistry. 20X magnification. Picture 
taken with the Olympus U-TV1X-2 camera system. (A) PAXgene-fixed WT prostate. (B) 
PAXgene-fixed TG prostate. (C) Formalin-fixed WT prostate. (D) Formalin-fixed TG 
prostate. The brown color is a representation of Ki-67 expression. Ki-67 expressing nuclei 
are marked with arrows 
 
 
5.2.2 Expression of Btg2 in transgenic mouse prostate tissue 
 
The expression of Btg2 in transgenic mouse prostate tissue was investigated by compar-
ing both WT and TG prostates. In addition, as previously, both fixatives were compared 
(PAXgene and formalin). The results are shown in figure 9 as a 20X magnification of the 
either ventral prostate, urethra, or ductus derefens. The pictures were taken with the 
Olympus U-TV1X-2 camera system using the automated Objective Imaging Surveyor 
scanning program. 
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The expression of Btg2 in PAXgene-fixed WT mouse is shown in figures 9A and 9B. 
Figure 9A represents the ventral prostate and 9B the urethra. The expression of Btg2 can 
be clearly seen, in figure 9A, as brown nuclear staining of the basal cells in the ventral 
prostate. The light-blue staining around the prostate represents the Mayer’s hematoxylin 
counterstaining of the smooth muscle. The Btg2 staining of the urethra in figure 9B shows 
a well-defined difference in the staining of the inner epithelium of the urethra, as com-
pared to the outer, blue-colored smooth muscle layer. This comparison was included to 
ensure the staining specificity between layers. The brown color, as seen on the edges, is 
caused by background staining.  
 
Figures 9C and 9D represent the immunohistochemistry of the PAXgene-fixed TG 
mouse. Both the ventral prostate (9C) and the ductus deferens (9D) are shown. As previ-
ously, the basal cells are stained brown – an indication of Btg2 expression. The ductus 
deferens, shown in figure 9D, shows a clear difference in the staining of the different cell 
types. The Btg2 staining of the ductus deferens of both formalin-fixed WT and TG pros-
tates is shown in figures 9E and 9F, respectively. When compared to the PAXgene fixa-
tion, no well-defined difference in the staining of the layers can be seen. As a result of 
the non-specific staining, no picture of the formalin-fixed ventral prostate is included.  
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FIGURE 9. Results of the Btg2 immunohistochemistry. 20X magnification. Picture taken 
with the Olympus U-TV1X-2 camera system. (A) PAXgene-fixed WT prostate (ventral). 
(B) PAXgene-fixed WT urethra. (C) PAXgene-fixed TG prostate (ventral). (D) 
PAXgene-fixed TG ductus deferens. (E) Formalin-fixed WT ductus deferens. (F) Forma-
lin-fixed TG ductus deferens. The brown color is a representation of Btg2 expression. 
The well-defined basal cell layer is marked with an arrow.  
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5.2.3 Expression of Pten in transgenic mouse prostate tissue 
 
The expression of Pten in transgenic mouse prostate tissue was investigated in two parts: 
First, by comparing specificity of the staining in the urethra and second, by comparing 
the expression in ventral prostate of both WT and TG prostates. In addition, the staining 
of both formalin fixation and PAXgene fixation were compared. The results of the Pten 
expression in the urethra are shown in figure 10, and the ventral prostate in figure 11. The 
pictures in both figures 10 and 11 were taken as a 20X magnification with the Olympus 
U-TV1X-2 camera system with the help of the automated Objective Imagining Surveyor 
scanning program. 
 
The expression of Pten in the urethra is shown in figure 10. In figures 10A–10D 
(PAXgene-fixed), a well-defined basal cell layer can be seen clearly as brown staining. 
This can be observed in both homozygous (Pten+/+) WT and TG prostates (figures 10A 
and 10B, respectively). The same is observed in both heterozygous (Pten+/-) WT and TG 
prostates (figures 10C and 10D, respectively). No clear difference in expression can be 
seen when comparing the homozygous prostates to the heterozygous ones. In comparison, 
the staining in figures 10E and 10F (formalin-fixed WT and TG prostate, respectively), 
is significantly more spread out: no well-defined basal cell layer can be seen. As a result, 
the formalin-fixed prostates were not included in the comparison in figure 11.   
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FIGURE 10. Results of the Pten immunohistochemistry. Comparison of staining speci-
ficity. 20X magnification of the urethra of both WT and TG prostates. Picture taken with 
the Olympus U-TV1X-2 camera system. Both PAXgene- and formalin-fixed prostates 
are included. (A) PAXgene-fixed homozygous (Pten+/+) WT prostate. (B) PAXgene-
fixed homozygous (Pten+/+) TG prostate. (C) PAXgene-fixed heterozygous (Pten+/-) WT 
prostate. (D) PAXgene-fixed heterozygous (Pten+/-) TG prostate. (E) Formalin-fixed WT 
prostate. (F) Formalin-fixed TG prostate. The brown staining is a representation of Pten 
expression. The basal cell layer, stained brown, is marked with an arrow 
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In figure 11, the Pten expression of both homozygous and heterozygous prostates is com-
pared. As established previously, specific expression of Pten is observed in the uroepi-
thelium. Expression of Pten in the homozygous (Pten+/+) WT prostate is shown in figure 
11A, and in figure 11B for the homozygous (Pten+/+) TG prostate. Heterozygous (Pten+/-
) Pten expression is shown in figure 11C for the WT prostate, and in figure 11D for the 
TG prostate.  
 
 
FIGURE 11. Results of the Pten immunohistochemistry. Comparison of Pten expression 
in PAXgene-fixed prostates. 20X magnification of the ventral prostate. Picture taken with 
the Olympus U-TV1X-2 camera system. (A) PAXgene-fixed homozygous (Pten+/+) WT 
prostate. (B) PAXgene-fixed homozygous (Pten+/+) TG prostate. (C) PAXgene-fixed het-
erozygous (Pten+/-) WT prostate. (D) PAXgene-fixed heterozygous (Pten+/-) TG prostate 
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6 DISCUSSION 
 
 
The objective of the thesis was to study the expression of several promising biomarkers 
in transgenic mouse prostate tissue. The purpose of the thesis was to establish protocols 
for the in situ hybridization of miR-32 and the immunohistochemistry of Ki-67, Btg2, and 
Pten – and to study their expression. Two different fixatives were used during the study: 
10% neutral buffered formalin and a commercial, alcohol-based PAXgene-fixative. Ad-
ditionally, to evaluate the level of expression in transgenic mouse prostate tissue, the re-
sults were compared to those of wild type prostates. The prostates were collected from 
ethically treated mice which were euthanized by following strict guidelines for the wel-
fare and use of animals in cancer research (Workman et al. 2010).   
 
The Molecular Biology of Prostate Cancer Group had previously established a transgenic 
mouse line (ARR2PB-miR32), expressing miR-32 in the prostate epithelium. To increase 
the frequency of prostatic lesions, the mouse line was crossbred with mice heterozygous 
for Pten tumor suppressor gene. Thus, the miRNA ISH technique was used to evaluate 
the presence of miR-32 expression in the epithelium. The immunohistochemistry of Ki-
67, Btg2, and Pten was further used to assist in the histopathological examination.   
 
Based on the results shown in figure 7, specific miR-32 expression can be detected in 
both wild type and transgenic prostates. Results of both negative and positive controls 
further confirm the specificity of the miR-32 expression, as seen in figure 7. However, 
when comparing figures 7D and 7H, no clear difference in miR-32 expression can be seen 
between the WT and TG mouse prostates. Also, no direct comparison between prostate 
lobes can be made, as the staining was uneven in certain lobes of the prostate.  
 
Uneven staining was further highlighted in the EDC-fixed samples, where entire sections 
of the prostate lobes were unstained. In addition, during the optimization attempts, EDC 
fixation seemed to cause a high amount of unspecific staining. This was observed in the 
controls as well, where the Scrambled DNA probe caused staining similar to specific 
miR-32 expression. Because of this, the results of the EDC-fixed miRNA ISH were not 
chosen for analysis, and are not included in figure 7.  
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As seen in figure 7, the expression of miR-32 is relatively low compared to U6 expres-
sion. In addition, the amount of background staining, as seen in figure 7G, is relatively 
high. High background staining can be caused, for example, by low hybridization tem-
perature or insufficient stringent washes (Exiqon 2011, 28). Thus, increasing the duration 
of the final stringent wash from 45 minutes to at least 60 minutes should be attempted. 
Extra attention should be paid on preheating the buffer, as the first post-hybridization 
washing buffer was not properly preheated to + 37 °C. According to Exiqon (2011, 28), 
some non-specific staining can be explained by insufficient preheating.  
 
According to Jones (2002, 565–566), the hybridization temperature should be 25 °C be-
low the melting point. In the thesis, the hybridization temperature was + 37 °C, which is 
lower than the recommended value (+ 50 °C). A higher hybridization temperature might 
improve the level of miR-32 expression (Jones 2002, 566). Low hybridization tempera-
ture can even cause the probe to hybridize with similar sequences, leading to false results 
(Exiqon 2011, 26). In addition, due to the length of the miRNA ISH protocol, the hybrid-
ization time had to be adjusted from a few hours to overnight. This may have negative 
effects on the hybridization of the probe, since the hybridization durations in commercial 
miRNA ISH protocols are typically only one hour (Exiqon 2011, 20). Additionally, the 
optimization attempts included changes in the proteinase-K concentration while other 
conditions, such as the presence of EDC fixation, did not remain constant.  
 
It is worth noting that RNAse contaminations are also possible, as the laboratory was not 
a proper RNAse-free environment, which may partially explain the lower-than-expected 
expression of miR-32, and some of the inconsistency with the results. In addition, as in 
situ hybridization is a highly challenging – and long – process, the short learning period 
and the time allotted to the technique might explain the varying results. In summary, a 
working miRNA ISH method was established, but due to the inconsistent miR-32 expres-
sion, further optimization and verification of the results should be attempted before mov-
ing to mice with confirmed prostatic lesions.  
  
The immunohistochemistry in this thesis was focused on establishing methods for the 
detection of Ki-67, Btg2, and Pten. Successful methods were established during the pro-
ject. The established protocol was identical for each antibody, thus providing a universal 
protocol for the immunohistochemistry of Ki-67, Btg2, and Pten.  Even with the use of a 
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multi-species secondary antibody (anti-rabbit and anti-mouse), the obtained results show 
specificity with all tested antibodies.   
 
Expression of Ki-67 in prostate tissue is linked to epithelial proliferation, which is a rel-
ative rare phenomenon in healthy prostate tissue. However, during prostate carcinogene-
sis, Ki-67 expression can be detected in the ventral prostate and the dorsolateral prostate. 
(Stanbrough et al. 2001.) As seen in figure 8, a few Ki-67 expressing nuclei can be de-
tected in both PAXgene-fixed WT and TG prostates, as well as in the formalin-fixed WT 
and TG prostates. However, some background staining of the stroma is seen in figure 8 – 
especially in the PAXgene-fixed samples. Based on the results by Kap et al. (2011), some 
difference in the immunohistochemistry is to be expected between PFPE and FFPE sam-
ples, indicating that the background staining should not be compared too closely. Increas-
ing the length of the washes should be attempted in order to try to remove some of the 
background staining. In addition, instead of the multi-species secondary antibody, a spe-
cific anti-rabbit antibody should be tested.  
 
As established by Stanbrough et al. (2001), Ki-67 expression should be minimal in 
healthy prostate tissue, with few positive nuclei. None of the prostates in figure 8 show 
prostatic lesions, such as PIN, which is an indication that significant Ki-67 expression is 
not expected. In addition, the prostate epithelium shows no unspecific staining, with well-
defined Ki-67 expressing nuclei. Based on these results, the established protocol for Ki-
67 leads to specific staining in the prostate epithelium in both PAXgene- and formalin-
fixed prostates. Thus, the protocol established here can be used for further Ki-67 staining 
in both PAXgene- and formalin-fixed prostates in the future, including samples with pros-
tatic lesions. 
 
BTG2 is an important tumor suppressor gene, responsible for many antiproliferative func-
tions, necessary for normal cell function. BTG2 protein is a nuclear protein, and is mainly 
expressed in basal cells. (Kawamura-Tsuzuku et al. 2004; Ficazzola et al. 2001.) In figure 
9, Btg2 expression can be clearly seen in the PAXgene-fixed prostate epithelium (9A and 
9C), urethra (9B), and ductus deferens (9D). As observed in Ficazzola et al (2001), the 
expression of Btg2 in the prostate is mainly in the basal cells. This can be seen in figures 
9A and 9C as well, where the Btg2 staining forms a clear basal cell layer inside the pros-
tate epithelium.  
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The Btg2 expression is specific in both WT and TG prostates, clearly visible as well-
defined borders between the epithelium (brown) and the smooth muscle (blue) in figure 
9. However, as seen in figures 9E and 9F, the formalin-fixed prostates show unspecific 
staining in both the epithelium and the muscle layer. Based on these results, the estab-
lished protocol shows specific Btg2 expression in the PAXgene-fixed prostates, but not 
in the formalin-fixed ones. Thus, the protocol established here can be used for further 
staining of Btg2 in PAXgene-fixed prostates, including prostates with prostatic lesions, 
such as PIN. However, more optimization should be attempted for formalin-fixed pros-
tates. 
 
The lack of specificity in the formalin-fixed prostates can be caused by multiple factors. 
Kap et al. (2011) observed that the formalin fixation and PAXgene fixation can have 
slight differences in the staining with immunohistochemistry. Thus, same conditions for 
the protocol might not apply for both fixation types. Based on the datasheet provided by 
Santa Cruz Biotechnology, there is no mention of a recommended technique for epitope 
unmasking. Because of this, the pH 9.0 HIER technique might not be optimal. As pH can 
matter greatly in the epitope unmasking, other buffers, such as the pH 6.0 citrate buffer 
should be tested (Kumar & Rudbeck 2009, 51–52). Specific anti-rabbit secondary anti-
body should be tested as well, instead of the multi-detection reagent. In addition, it is 
worth noting that the FFPE samples used here were stored for several months in the cold 
room, which may affect the results in immunohistochemistry. This should be tested by 
repeating the protocol with fresh tissue sections.  
 
Phosphatase and tensin homolog (PTEN) is a well-established tumor suppressor gene. It 
is responsible for modulation the Akt-signaling pathway, thus having an important part 
in the regulation of cell cycle progression. (Celebi et al. 2000; Kanamori et al. 2001; 
Ohigashi et al. 2005.) According to Wang et al. (2003), Pten is expressed in the nuclear 
and cytoplasmic compartments of WT mice, and also in the prostate epithelium and the 
stromal cells. In figure 10, Pten expression can be clearly seen in the basal cells of the 
urethra. However, clear expression can only be seen in the PAXgene-fixed prostates (Fig-
ures 10A–10D). Thus, the formalin-fixed samples were not included in further analysis. 
In figure 11, a low level of Pten expression can be seen in all PAXgene-fixed samples, 
including the WT and TG prostates, as well as the homozygous and heterozygous varia-
tions.  
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As the ARR2PB-miR32 mouse line is crossbred with mice heterozygous for Pten tumor 
suppressor gene, Pten expression should be significantly lower in the transgenic mouse 
prostate (Blando et al. 2009). In figure 11 this difference cannot be clearly seen: the level 
of staining appears quite similar in all homozygous and heterozygous variants. However, 
it should be noted that immunohistochemistry is not a quantitative method, thus the in-
tensity of the Pten expression between mouse lines should not be directly compared. As 
the expression of Pten in the formalin-fixed samples is not suitable (figures 10E and 10F), 
further optimization should be attempted. As with Ki-67 and Btg2, the pH 6.0 HIER 
method should be tested, along with the specific anti-rabbit secondary antibody. Based 
on these results, the established method here can be used for further Pten immunohisto-
chemistry with PAXgene-fixed samples, including samples with prostatic lesions.   
 
In conclusion, the objective and purpose of the thesis were largely accomplished. Suc-
cessful immunohistochemical staining methods were obtained for Ki-67 with both for-
malin fixation and PAXgene fixation, for Btg2 with PAXgene fixation, and for Pten with 
PAXgene fixation. A working protocol for the in situ hybridization of miR-32 in 
PAXgene-fixed mice was also established here – although with a relatively weak signal 
and inconsistent staining. Ki-67 was shown to have a low level of specific expression in 
the prostate of both WT and TG mice, with no clear difference in expression. Btg2 was 
shown to be expressed in the basal cell layer of both WT and TG prostates. Specificity 
was confirmed by specific expression in the urethra (WT) and in the ductus deferens (TG). 
Expression of Pten was shown to be clearly visible in the basal cell layer of the urethra 
and prostate tissue in both WT and TG mice, with no clear difference in expression. And 
last, a low level of miR-32 expression was seen in the prostate epithelium of of both WT 
and TG mice.  
 
In the future, the results obtained in this thesis can help the Prostate Cancer Research 
Group to investigate mouse lines with confirmed prostatic lesions, in order to investigate 
the role of these biomarkers in prostate carcinogenesis, and in the formation of castration-
resistance. In addition, these methods will help clarify the success of the transgenic 
ARR2PB mouse line, established by the group. Hopefully, with further research on these 
putative biomarkers, clinical biomarkers of aggressive prostate cancer – and treatment 
options – are one step closer to reality.  
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APPENDICES 
Attachment 1. Reagent list for the in situ hybridization  
Solution Content 
Proteinase-K 
5.0 µg/ml Proteinase-K (Sigma-Al-
drich) in Proteinase-K buffer 
Proteinase-K buffer 
5 mM Tris-HCl, 1 mM EDTA, 1 mM 
NaCl in DEPC-treated H2O (auto-
claved) 
Glycine buffer 0.2% Glycine in PBS 
Imidazole buffer 
0.13 M 1-methylimidazole, 300 mM 
NaCl in DEPC-treated H2O pH 8.0 
Prehybridization buffer 50% formamide, 5X SSC 
Hybridization buffer 
50% formamide, 5X SSC, 10% Dex-
tran Sulphate Sodium, 500 µg/ml 
Salmon sperm (denatured), 0.02% 
BSA 
U6 probe 
0.5 nM U6 probe (Exiqon, LOT: 
63249191) in hybridization buffer. 
Probe denatured before use 
Scrambled DNA probe 
25 nM Scrambled DNA probe (Ex-
iqon, LOT: 63249176) in hybridiza-
tion buffer. Probe denatured before 
use 
miR-32 probe 
25 nM hsa-miR-32 probe (Exiqon, 
batch 152466) in hybridization buffer. 
Probe denatured before use 
1st Stringency wash buffer 5X SSC, 50% formamide mix 
2nd  Stringency wash buffer 2X SSC, 50% formamide mix 
3rd Stringency wash buffer 0.2X SSC, 50% formamide mix 
10X blocking solution 
10% Blocking reagent in Maleic acid 
buffer (Roche) 
1X blocking solution 
10X blocking solution diluted to 1:10 
with 1X Maleic acid buffer 
Anti-DIG-HRP 
1:800 dilution of Anti-DIG-HRP in 1X 
blocking solution 
DIG Amplification working solution 
1:50 
1:800 dilution of DIG amplification 
stock solution in dilution reagent 
(PerkinElmer) 
Anti-DIG-AP 
1:800 dilution of Anti-DIG-AP in 1X b 
locking solution, 2% sheep serum 
 
AP substrate working solution 
1:50 dilution of NBT/BCIP stock solu-
tion (Roche) in 0.1 M Tris-HCl, 0.1 M 
NaCl pH 8.5 
KTBT (AP stop solution) 
50 mM Tris-HCl, 150 mM NaCl, 10 
mM KCl in DEPC-treated H2O (auto-
claved) 
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Attachment 2. Reagent list for the immunohistochemistry  
Solution Content 
Endogenous Peroxidase 3% H2O2 Commercial (VWR, LOT: 12B240024) 
TE buffer 
10 mM Tris Base, 1 mM EDTA, 
0.05% Tween 20, pH 9.0 
Ki-67 antibody (MM1) 
Novocastra™ Lyophilized Mouse 
Monoclonal Antibody Ki67 Antigen 
MM1 (Leica Biosystems, LOT: 
111870) 
Ki-67 antibody (SP6) 
Anti-Ki-67 Clone: SP6,  Lab Vision 
Rabbit Monoclonal Antibody (Thermo 
Scientific, LOT: 9106S 1010G) 
Btg2 antibody 
Btg2 (H-50): sc-33775 (Santa Cruz 
Biotechnology) rabbit polyclonal anti-
body 
Pten antibody 
Pten (138G6) Rabbit mAb (Cell Sig-
naling Technology) rabbit monoclonal 
antibody (LOT: 12) 
Primary antibody diluent 
Normal Antibody Diluent (Immuno-
logic, LOT: 211013) 
Secondary antibody 
Histofine Simple Stain MAX PO 
(multi) Universal Immuno-peroxidase 
Polymer Anti-Mouse and -Rabbit  
(Nichirei Biosciences, LOT: H1312-1) 
ImmPACT DAB substrate 
1:40 dilution of ImmPACT DAB Chro-
mogen in DAB Diluent (Vector Labor-
atories, LOT: Z0703) 
Counterstain solution Mayer’s Hematoxylin (Histolab) 
 
